首页> 外文期刊>Advances in anatomic pathology >Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity.
【24h】

Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity.

机译:肌腱和腱膜的透明细胞肉瘤:历史的观点,并向实体背后的人致敬。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Clear cell sarcoma of tendons and aponeuroses is a unique sarcoma initially described by Dr Franz M. Enzinger. The tumor has a proclivity to involve the tendons and aponeuroses of distal extremities of relatively young individuals and is characterized by multiple local recurrences with late metastases and a high rate of tumor deaths. Since its seminal description in 1965, there have been many studies verifying the uniqueness of this entity and probing its differentiation. Ultrastructural and immunohistochemical studies have shown melanocytic differentiation, whereas molecular genetic studies have shown cytogenetic rearrangements resulting in a EWSR1-ATF1 fusion gene that is characteristic but not entirely unique for clear cell sarcoma (similar fusion genes are also seen in angiomatoid fibrous histiocytoma). Detection of this fusion gene and the absence of BRAF gene mutations clearly distinguish clear cell sarcoma from cutaneous melanoma. Adverse prognostic factors identified to date include larger tumor size and any microscopic tumor necrosis. Surgery is the mainstay of treatment for this high grade sarcoma, with chemotherapy having little effect. Although the melanocytic differentiation of clear cell sarcoma is indisputable, its precise lineage remains unclear. Thus, clear cell sarcoma maintains the status of a unique yet enigmatic clinicopathologic entity of ever increasing complexity 40 years after its original description by an extraordinarily gifted man.
机译:肌腱和腱膜的透明细胞肉瘤是一种独特的肉瘤,最初由Franz M. Enzinger博士描述。肿瘤倾向于累及相对年轻个体的远端四肢腱和腱膜,其特点是多发局部复发,晚期转移和高死亡率的肿瘤。自从1965年对其进行了开创性的描述以来,已有许多研究证实了该实体的独特性并探讨了其区别。超微结构和免疫组织化学研究显示了黑素细胞的分化,而分子遗传学研究显示了细胞遗传学的重排导致了EWSR1-ATF1融合基因,该基因是透明细胞肉瘤的特征但并非完全独特(在血管瘤样纤维组织细胞瘤中也观察到了类似的融合基因)。对该融合基因的检测和BRAF基因突变的缺失清楚地将透明细胞肉瘤与皮肤黑色素瘤区分开。迄今为止确定的不良预后因素包括更大的肿瘤大小和任何微观的肿瘤坏死。手术是治疗这种高度肉瘤的主要手段,化学疗法效果不佳。尽管透明细胞肉瘤的黑素细胞分化是无可争辩的,但其确切的血统仍然不清楚。因此,透明细胞肉瘤维持了独特但神秘的临床病理学实体的地位,这种实体在一个非常有天赋的人对它的最初描述之后的40年中变得越来越复杂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号